Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved surviv…

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by…

Click here to view the original article.